Eur Arch Otorhinolaryngol:过敏性鼻炎中IL-13和CD14基因单核苷酸多态性分析

2018-05-07 AlexYang MedSci原创

最近,有研究人员进行了元分析,目的是研究白介素-13(IL-13)和分化群14(CD14)基因的单核苷酸多态性情况和过敏性鼻炎(AR)的风险情况。研究人员筛选了在7个数据库中的数据,包括了Pubmed、Medline、Web of Science、Embase、China Biology Medicine disc、 Wanfang和中国学术期刊网络出版数据库。研究人员利用让步比(ORs)和95%

最近,有研究人员进行了元分析,目的是研究白介素-13(IL-13)和分化群14(CD14)基因的单核苷酸多态性情况和过敏性鼻炎(AR)的风险情况。研究人员筛选了在7个数据库中的数据,包括了Pubmed、Medline、Web of Science、Embase、China Biology Medicine disc、 Wanfang和中国学术期刊网络出版数据库。研究人员利用让步比(ORs)和95%置信区间(CIs)来评估等位、显性和隐性之间的相关性。

研究发现,总共有8547名参与者(3223个案例和5324名对照)的12个相关研究调查了IL-13 SNP rs20541;总共有4580名参与者(1411个案例和3169名对照)的5个研究调查了 IL-13 SNP rs1800925,总共有2310名参与者(1174个案例和1127名对照)的9个研究评估了 CD14 SNP rs2569190。研究人员发现了 IL-13 SNP rs20541 的A等位基因与AR风险的增加相关(OR 1.19, 95% CI 1.11-1.28, P<0.001)。组群的分层研究在亚洲产生了显著的结果(OR 1.21, 95% CI 1.11-1.32, P<0.001),但是在白种人中没有显著的结果(OR 1.14, 95% CI 1.00-1.30, P=0.051)。另外,研究人员在黄种人和白种人之间没有发现 IL-13 SNP rs1800925 和 CD14 SNP rs2569190与AR风险之间的相关性。

最后,研究人员指出,他们的发现表明了IL-13 SNP rs20541在黄种人中与AR风险显著相关,但不存在与白种人中。并且积累的证据并没有支持 IL-13 SNP rs1800925 和 CD14 SNP rs2569190与AR风险的相关性。

原始出处:

Chen ML, Zhao H, Huang QP et al. Single nucleotide polymorphisms of IL-13 and CD14 genes in allergic rhinitis: a meta-analysis. Eur Arch Otorhinolaryngol. 23 April 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1782699, encodeId=7c641e82699ae, content=<a href='/topic/show?id=ebe8426953' target=_blank style='color:#2F92EE;'>#CD14#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4269, encryptionId=ebe8426953, topicName=CD14)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 03 13:58:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945620, encodeId=817819456207f, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Fri Aug 10 21:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046963, encodeId=8af92046963d0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Sep 27 14:58:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471746, encodeId=f3fe14e1746ec, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508214, encodeId=cabc1508214b2, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629256, encodeId=3423162925676, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312927, encodeId=64be31292e51, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon May 07 20:47:14 CST 2018, time=2018-05-07, status=1, ipAttribution=)]
    2018-11-03 一叶知秋
  2. [GetPortalCommentsPageByObjectIdResponse(id=1782699, encodeId=7c641e82699ae, content=<a href='/topic/show?id=ebe8426953' target=_blank style='color:#2F92EE;'>#CD14#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4269, encryptionId=ebe8426953, topicName=CD14)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 03 13:58:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945620, encodeId=817819456207f, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Fri Aug 10 21:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046963, encodeId=8af92046963d0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Sep 27 14:58:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471746, encodeId=f3fe14e1746ec, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508214, encodeId=cabc1508214b2, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629256, encodeId=3423162925676, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312927, encodeId=64be31292e51, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon May 07 20:47:14 CST 2018, time=2018-05-07, status=1, ipAttribution=)]
    2018-08-10 xsm918
  3. [GetPortalCommentsPageByObjectIdResponse(id=1782699, encodeId=7c641e82699ae, content=<a href='/topic/show?id=ebe8426953' target=_blank style='color:#2F92EE;'>#CD14#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4269, encryptionId=ebe8426953, topicName=CD14)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 03 13:58:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945620, encodeId=817819456207f, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Fri Aug 10 21:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046963, encodeId=8af92046963d0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Sep 27 14:58:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471746, encodeId=f3fe14e1746ec, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508214, encodeId=cabc1508214b2, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629256, encodeId=3423162925676, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312927, encodeId=64be31292e51, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon May 07 20:47:14 CST 2018, time=2018-05-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1782699, encodeId=7c641e82699ae, content=<a href='/topic/show?id=ebe8426953' target=_blank style='color:#2F92EE;'>#CD14#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4269, encryptionId=ebe8426953, topicName=CD14)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 03 13:58:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945620, encodeId=817819456207f, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Fri Aug 10 21:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046963, encodeId=8af92046963d0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Sep 27 14:58:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471746, encodeId=f3fe14e1746ec, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508214, encodeId=cabc1508214b2, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629256, encodeId=3423162925676, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312927, encodeId=64be31292e51, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon May 07 20:47:14 CST 2018, time=2018-05-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1782699, encodeId=7c641e82699ae, content=<a href='/topic/show?id=ebe8426953' target=_blank style='color:#2F92EE;'>#CD14#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4269, encryptionId=ebe8426953, topicName=CD14)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 03 13:58:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945620, encodeId=817819456207f, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Fri Aug 10 21:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046963, encodeId=8af92046963d0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Sep 27 14:58:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471746, encodeId=f3fe14e1746ec, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508214, encodeId=cabc1508214b2, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629256, encodeId=3423162925676, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312927, encodeId=64be31292e51, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon May 07 20:47:14 CST 2018, time=2018-05-07, status=1, ipAttribution=)]
    2018-05-09 jjjiang0202
  6. [GetPortalCommentsPageByObjectIdResponse(id=1782699, encodeId=7c641e82699ae, content=<a href='/topic/show?id=ebe8426953' target=_blank style='color:#2F92EE;'>#CD14#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4269, encryptionId=ebe8426953, topicName=CD14)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 03 13:58:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945620, encodeId=817819456207f, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Fri Aug 10 21:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046963, encodeId=8af92046963d0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Sep 27 14:58:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471746, encodeId=f3fe14e1746ec, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508214, encodeId=cabc1508214b2, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629256, encodeId=3423162925676, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312927, encodeId=64be31292e51, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon May 07 20:47:14 CST 2018, time=2018-05-07, status=1, ipAttribution=)]
    2018-05-09 xzw120
  7. [GetPortalCommentsPageByObjectIdResponse(id=1782699, encodeId=7c641e82699ae, content=<a href='/topic/show?id=ebe8426953' target=_blank style='color:#2F92EE;'>#CD14#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4269, encryptionId=ebe8426953, topicName=CD14)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Nov 03 13:58:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945620, encodeId=817819456207f, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Fri Aug 10 21:58:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046963, encodeId=8af92046963d0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Thu Sep 27 14:58:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471746, encodeId=f3fe14e1746ec, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508214, encodeId=cabc1508214b2, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629256, encodeId=3423162925676, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed May 09 10:58:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=312927, encodeId=64be31292e51, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon May 07 20:47:14 CST 2018, time=2018-05-07, status=1, ipAttribution=)]
    2018-05-07 戒馋,懒,贪

    谢谢分享学习了

    0

相关资讯

Int Arch Otorhinolaryngol:白介素-33水平在过敏性鼻炎患者中免疫治疗治疗效果中的作用研究

过敏性鼻炎(AR)影响了多达40%的人口比例,并且能够导致鼻痒症、充血、打喷嚏和流清鼻涕。最近,有研究人员在患有AR的病人中,进行了旨在评估花粉免疫治疗(IT)前后临床症状和血清白介素(IL)-33的水平变化的情况。研究人员在10名非过敏性的健康对照和45名患有AR的病人中确定了总症状得分和总免疫球蛋白E(lgE)以及IL-33。参与的病人被分成3个小组:GI组(病人没有进行IT),GII(病人进

Int Arch Allergy Immunol:气道变应性炎症患者中,第二组先天性淋巴细胞的增加与嗜酸性粒细胞相关

辅助T(Th2)类型响应被认为是过敏性气道疾病的本质,包括了哮喘和过敏性鼻炎(AR)。然而,有研究表明过敏性气道炎症同样依赖于先天免疫,并且与第二组先天性淋巴细胞(ILC2s)密切相关。最近,有研究人员在哮喘患者、哮喘和过敏性鼻炎患者以及健康个体中评估了ILC2的水平,并且尝试分析调查了临床数据和ILC2水平之间的关系。研究发现,哮喘患者和患有哮喘的过敏性鼻炎病人与健康对照相比,具有更低水平的IL

J Asthma:秋天花粉诱导的过敏性鼻炎中,血清特异性lgE水平与哮喘相关性研究

艾草和葎草花粉在中国北方是2中最为重要的秋季过敏过敏原。在2001年的代表性数据表明了过敏性鼻炎总是领先或者是同时和中国北方的秋季花粉过敏病人哮喘发生。最近,有研究人员利用代表性的数据调查了血清特异性lgE (slgE)水平与葎草和/或艾草花粉的相关性,时间点事秋季花粉诱导的过敏性鼻炎患者哮喘开始时。研究包括了1096名秋季花粉病患者,并且进行了面对面交谈和对葎草和艾草的slgE测试,阐释和记录了

Asian Pac J Allergy Immunol:患有或不患有过敏性鼻炎的哮喘儿童中,Th17细胞调控的免疫应答比较

最近,有研究人员在患有或者不患有过敏性鼻炎的哮喘儿童中,调查了Th17细胞调控的免疫应答是否具有差异。研究人员在儿童中进行了一个案例-对照比较试验,其中包括67名哮喘(AS)儿童,50儿童患有过敏性鼻炎,52名儿童同时患有AS和AR(ASR),25名为传染性鼻炎(IR)和55名健康对照(HC)。研究人员使用的技术包括流式细胞仪、酶联免疫吸附试验等。研究发现,组内比较阐释了Th17细胞在ASR组中水

Allergy Asthma Immunol Res:过敏性鼻炎患者中外周B细胞子类型分析

之前证据表明B细胞能够同时促进和抑制过敏性疾病的发展和恶化。然而,在过敏性鼻炎(AR)患者中,B细胞类型的特性情况还没有很好的阐释。最近,有研究人员进行了旨在分析AR患者外周血B细胞类型特性情况的研究。研究包括了57名AR患者和54名健康对照,并且通过流式细胞仪对所有参与者的外周血B细胞类型进行了分析。并且还通过酶联免疫试验测量了血清总lgE和lgE分泌到培养的外周血单核细胞(PBMCs)的浓度情

Allergy Asthma Proc:过敏性鼻炎和花粉过敏儿童中,关于哮喘在围产期风险因子的研究

流行病学研究结果确定了学龄期儿童哮喘的一些风险因子。最近,有研究人员为了调查是否父母和围产期风险因子、以及婴儿的喂养方式与患有花粉过敏和过敏性鼻炎儿童的哮喘相关。研究包括了293名儿童(200名男孩(68.3%)),平均年龄为10.2岁(范围为7.4到13岁)。总共有109名儿童(37.2%)患有伴随的哮喘。在患有哮喘的儿童中,鼻炎症状的起始平均年龄更小(5.3岁 [IQR, 4.0-8.0 岁]